three-year cumulative incidence of relapse for patients in the LPA96 and LPA99 studies was 17.2 and 7.5 percent, respectively (P=0.008). Patients treated with ATRA in consolidation therapy showed an overall reduction in the relapse rate from 20.1 to 8.7 percent (P=0.004). In intermediate-risk patients the rate decreased from 14.0 to 2.5 percent (P= 0.006). This improved antileukemic efficacy also translated into significantly better disease-free and overall survival. A risk-adapted strategy combining anthracycline monochemotherapy and ATRA for induction and consolidation therapy of newly diagnosed APL results in improved antileukemic efficacy and a high degree of compliance.
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INTRODUCTION
The current recommendations for treatment of patients with newly diagnosed acute promyelocytic leukemia (APL) include all-trans-retinoic acid (ATRA) and anthracyclinebased chemotherapy for remission induction, anthracycline-based chemotherapy for consolidation, and ATRA with low dose chemotherapy for maintenance. 1 The use of ATRA during consolidation has not been explored.
Using ATRA and anthracycline monochemotherapy (LPA96 study), the Spanish cooperative group PETHEMA (Programa de Estudio y Tratamiento de las Hemopatías Malignas) recently reported outcome results 2 similar to those obtained in other studies 3, 4, 5, 6, 7, 8 using ATRA with anthracycline-based chemotherapy combinations. Aiming to improve the antileukemic efficacy of this protocol in patients with increased relapse risk, a new trial based on a risk-adapted strategy was started in November 1999 (LPA99 study).
In this study, intermediate-and high-risk patients 9 received ATRA during consolidation therapy in combination with moderately reinforced anthraycline monochemotherapy.
We report here the results obtained in 426 consecutive patients with newly diagnosed PML/RARα positive APL who were enrolled in these two consecutive studies.
METHODS

ELIGIBILITY
The eligibility criteria for both studies were a diagnosis of de novo APL with demonstration of the t (15;17) or PML/RARα rearrangements, normal hepatic and renal function, no cardiac contraindications to anthracycline chemotherapy, and an Eastern Cooperative
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STUDY DESIGN
Induction therapy
The induction regimen consisted of oral ATRA (45 mg/m 2 /d), divided into two daily doses, which was maintained until complete hematological remission, or for a maximum of 90 days, and idarubicin (12 mg/m 2 /d) given as an intravenous bolus dose on days 2, 4, 6 and 8.
For patients 20 years of age or younger, the ATRA was adjusted to 25 mg/m 2 /d. From
November 1999, the dose of idarubicin on day 8 was omitted for patients older than 70 years of age.
Treatment was started as soon as a diagnosis of APL was made by cytological criteria. 10, 11 For patients in whom the diagnosis was not confirmed by genetic studies, ATRA treatment was withdrawn and alternative chemotherapy was given at the physician's discretion.
Consolidation therapy
Between November 1996 and October 1999 (LPA96 study), all patients in complete remission (CR) received three monthly consolidation courses. 
DEFINITIONS AND STUDY ENDPOINTS
Complete remission and relapse were defined according to the National Cancer Institute criteria. 14 Early death was defined as death occurring during induction therapy or during the period of aplasia after chemotherapy. Molecular remission was defined as the disappearance on an ethidium bromide gel of the PML/RARα specific band visualized at diagnosis, using RT-PCR assays with a sensitivity level of one cell in 10 Risk of relapse was established at diagnosis according to a predictive model based on patient leukocyte and platelet count at diagnosis, as reported elsewhere. 9 Low-risk patients had a white blood cell (WBC) count less than 10 × 10 9 /L and a platelet count greater than 40 × 10 9 /L; intermediate-risk patients had a WBC count less than 10 × 10 9 /L and a platelet count less than 40 × 10 9 /L; and high-risk patients had a WBC count equal to or greater than 10 × 10 9 /L.
STATISTICAL ANALYSIS
Rates of CR were evaluated using contingency tables. Unadjusted time-to-event analyses
were performed using the Kaplan-Meier estimate, 16 and, for comparisons, the log-rank tests. 17 The probability of relapse was also estimated by the cumulative incidence method (marginal probability). 18, 19 Overall survival (OS) was calculated from the date of starting induction therapy, while cumulative incidence of relapse (CIR) and disease-free survival (DFS) were calculated from the date of CR. In the analysis of DFS, relapse and death in CR were considered uncensored events, whichever occurred first. For cumulative incidence analysis, death in CR was considered as a competing cause of failure. For all estimates in which the event 'relapse' was considered as an endpoint, hematological and molecular relapses, as well as molecular persistence, were each considered as uncensored events. For overall survival, an event was death from any cause, with any patients alive at last follow- 20 Except for the cumulative incidence method, computations were performed using the 4F, 1L and 2L programs from the BMDP statistical library (BMDP Statistical Software Inc, Los Angeles, CA).
RESULTS
ACCRUAL AND PATIENT CHARACTERISTICS
Between November The main clinical and biological characteristics of the 426 patients evaluable for induction are shown in Table 1 .
INDUCTION THERAPY
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Hematological and molecular responses
Three hundred eighty-four of the 426 evaluable patients achieved hematological CR (90 percent; 95 percent confidence interval, 87 to 92 percent). The remaining 42 were considered as failures due to early death or resistance (3 patients). Eleven early deaths were attributable to infection, 25 to cerebral, intestinal or pulmonary hemorrhage, two to ATRA syndrome, and the remaining one to an unknown cause. The response rates and causes of induction death were similar in both the LPA96 and LPA99 studies ( Table 2 ). For patients older than 70 years, the response rate was 60% (6/10) and 75% (9/12) for those receiving four (LPA96) and three doses (LPA99) of idarubicin, respectively. This difference was not statistically significant. 
Retinoic acid syndrome
'Definitely present' retinoic acid syndrome was diagnosed in 18 patients (4.2 percent), two of whom died from it, whereas an 'indeterminate' retinoic acid syndrome was reported in 105 (24.6 percent). Despite prednisone prophylaxis, the incidence of 'indeterminate' and 'definitely present' retinoic acid syndrome in the LPA99 study (22.9 percent and 4 percent, respectively) did not differ from those in the LPA96 trial (25.9 percent and 4.6 percent, respectively). 
The ATRA therapy was temporarily discontinued in 68 patients (16 percent) due to a presumed retinoic acid syndrome. This therapy was restarted at a median time of five days (range, 2 to 17). In 22 additional patients, ATRA was definitively discontinued after a median of 15 days of treatment (range, 7 to 19).
CONSOLIDATION THERAPY
Molecular response
RT-PCR tests for PML/RARα were carried out in 359 cases at the end of consolidation therapy (95 percent) ( Table 3 
one because she became pregnant). The remaining 375 patients (99.2 percent) completed the three consolidation courses as scheduled.
MAINTENANCE THERAPY
All of the 378 patients alive after completing consolidation therapy proceeded to receive maintenance therapy. Cytopenias, especially neutropenia, and slight liver function test abnormalities were commonly observed in this phase, often requiring dose reduction or temporary discontinuation of chemotherapy. Three deaths in remission occurred during maintenance in patients aged 73, 78, and 33 due to unknown cause, infection and epilepsy status, respectively. The latter patient had had cerebral hemorrhage at presentation.
OUTCOME
In addition to the seven cases of molecular persistence, 32 relapses occurred among the 384 patients who achieved CR, 22 out of 157 in the LPA96 study and 10 out of 227 in the LPA99 study (Table 3) . Five additional patients died after developing other malignancies (3 AML and 2 colon cancer).
Cumulative incidence of relapse
For patients in the LPA96 study, with a median follow-up of 48 months for surviving patients, the CIR rate was 17.2 percent, whereas for patients in the LPA99 study, with a median follow-up of 21 months, it was 7.5 percent (P=0.008) (Fig. 1A) . Excluding low-risk patients to better evaluate the impact of risk-adapted consolidation, the three-year CIR rates were 20.1 percent in the LPA96 study and 8.7 percent in the LPA99 study (P=0.004) (Fig.   1B ).
For personal use only. on January 19, 2018. by guest www.bloodjournal.org From For low-risk patients from both studies, the six-year CIR was 6.4 percent. For patients in the LPA99 study, the three-year CIR for low-intermediate-and high-risk patients were 3, 2.5 and 21 percent, respectively, whereas in the LPA96 study, they were 6.1, 14 and 34.2 percent (P=0.8, P=0.006 and P=0.08) (Fig. 1C) . This led to a CIR of 2.6 percent for both low-and intermediate-risk groups in the LPA99 trial when they were analyzed together.
Disease-free survival
The three-year DFS rates were 81% ± 6% in the LPA96 study and 90% ± 5% in the LPA99 study (P=0.008) ( Fig. 2A) . Excluding low-risk patients, the three-year DFS rates were 77% ± 8% in the LPA96 study and 90% ± 6% in the LPA99 study (P=0.002) (Fig.   2B ).
For low-risk patients, the six-year DFS rate was 86% ± 10%. For patients in the LPA99 study, the three-year DFS rates for low-intermediate-and high-risk patients were 93% ± 8%, 97% ± 4% and 77% ± 14%, respectively, whereas in the LPA96 study, they were 97% ± 6%, 82% ± 8% and 66% ± 15% (P=0.4, P=0.002 and P=0.05) (Fig. 2C) .
Overall survival
The probability of remaining alive after three years was 78% ± 6% in the LPA96 study and 85% ± 5% in the LPA99 study (P=0.2) (Fig. 3A) . For patients younger than 70 years, these estimates were 79% ± 6% and 88% ± 5% (P=0.1). Excluding low-risk patients, the threeyear OS rate for patients in the LPA99 study (86% ± 5%) was significantly higher than for those in the LPA96 study (73% ± 7% ; P=0.02) (Fig. 3B) . Although these apparent improvements are based on historical comparisons, there are several features of the present study that reduce the chance of bias. All participating institutions registered all patients with newly diagnosed APL, regardless of any criteria that may lead to a selection bias. Moreover, eligibility criteria were unchanged throughout the study, and included obligatory genetic diagnosis, a prerequisite that was accomplished by only three of the other major series combining ATRA and chemotherapy. 3, 6, 8 Given the sequential nature of the studies, patients in the LPA99 series had a shorter follow-up than those in the LPA96. Notwithstanding, the LPA99 study contains the largest series reported so far for a single therapeutic option, and its follow-up is similar to those reported in the major trials published to date.
Induction results in the LPA96 and LPA99 studies confirmed the virtual absence of leukemia resistance using ATRA and idarubicin treatment alone. Induction failure rates remained unchanged over the study period, in spite of prophylactic administration of tranexamic acid and corticosteroids in the LPA99 study to reduce hemorrhage-and retinoic acid syndrome-associated mortality, respectively. In line with these findings, Avvisati et 21 demonstrated a reduction of hemorrhagic episodes using tranexamic acid prophylaxis,
although they failed to demonstrate any impact on hemorrhage-associated mortality.
That concomitant ATRA and chemotherapy results in higher antileukemic efficacy when used for induction 3, 5 and maintenance therapy 5 provided a rationale for using such a combination in consolidation. In addition, the low toxicity during consolidation therapy observed in the interim analysis of the LPA96 study 2 suggested that idarubicin dose could be raised safely. This reinforcement appeared to improve the rate of molecular remissions after consolidation therapy in intermediate-and high-risk patients while maintaining a very high degree of treatment compliance without increasing toxic deaths. In contrast, most recent trials 3, 4, 5, 6, 7, 8 reported important toxicity during consolidation, leading to a variable but significant number of patients receiving less treatment than scheduled.
Although the optimal schedule for monitoring minimal residual disease by RT-PCR in APL is not well established, 22 the experience of the PETHEMA studies confirms that molecular status after induction has no predictive value on patient outcome. In contrast, molecular persistence of residual disease and molecular relapse after consolidation are almost invariably observed in high-risk patients. These findings suggest that such stringent molecular monitoring may not be cost-effective for low-and intermediate-risk patients.
The significant improvement of the antileukemic efficacy in the LPA99 study, compared with the LPA96 study, was certainly caused by the modified consolidation therapy, although it is unclear which part of the reinforced therapy (ATRA or chemotherapy or both) may have led to the impact observed in the outcome.. However, there may be a significant role for ATRA, as has been demonstrated for induction 3, 5 and maintenance therapy. 5 Thus the use of ATRA combined with chemotherapy for consolidation therapy for low-risk
patients is warranted. Like it has been demonstrated for induction and maintenance therapy in other previous studies, 3, 5 the results of the present study also suggest that the benefit provided by the modified consolidation therapy in terms of relapse rate was less important in patients with initially higher WBC counts (P=0.08 versus P=0.006).
This 7.5 percent CIR at three-years in the overall LPA99 series, with 2.6 percent in the low and intermediate group (together accounting for 75 percent of total patients), compares favorably with all other studies published so far. Although the antileukemic benefit provided by the addition of ATRA to consolidation therapy should be definitively settled in randomized studies or with longer follow up, we believe that the current consensus on the simultaneous administration of ATRA and chemotherapy for induction and maintenance in the front line therapy of APL could be extended to the consolidation phase. In addition to its higher antileukemic efficacy, this combination also results in a higher degree of compliance and lower toxicity, compared with polychemotherapy combinations. Finally, risk-adapted strategies focusing on patients with hyperleukocytosis at presentation should be the major subject of future studies. or Risk-adapted Consolidation (LPA99 study).
P values were calculated with use of the log-rank test.
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